EUCTR2011-004555-39-ES进行中（未招募）不适用
A Phase 2, Randomized, Double-blind, Placebo-controlled, Parallel group, Adaptive, combined Proof of Concept and Dose-Finding study to investigate Efficacy, Safety, Pharmacodynamics and Pharmacokinetics of ASP3652 in the treatment of female subjects with Bladder Pain Syndrome / Interstitial Cystitis - AMARANTH
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 300
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Female
入选标准
- •At Visit 1:
- •1.Written informed consent has been obtained. Institutional Review Board (IRB)-/Independent Ethics Committee (IEC)-approved written Informed Consent and privacy language as per national regulations must be obtained from the subject or legally authorized representative prior to any study-related procedures (including withdrawal of prohibited medication, if applicable).
- •2.Is female, 18 years of age or older and of Caucasian (white) ethnic background.
- •3.Has previously been diagnosed with BPS/IC; i.e, pelvic pain, pressure or discomfort perceived to be related to the urinary bladder accompanied by at least one other urinary symptom such as persistent urge to void or frequency, for at least 3 months prior to screening in absence of urinary infection or other obvious pathology or identifiable causes.
- •4.Has a score of 4 or greater on the 11-point (0-10) NRS for average pain over the previous week, which is item 4 of the F GUPI.
- •5.Must practice a highly reliable method of birth control. When of childbearing potential, subjects must agree to maintain highly effective birth control during the study. A highly effective method of birth control is defined as those which result in a low failure rate (CPMP/ICH/286/95 modified) of less than 1% per year when used consistently and correctly such as implants, injectables, combined oral contraceptives, some intra-uterine devices (IUDs), sexual abstinence or vasectomized partner.
- •6.Is willing and able to comply with study requirements (e.g, complete questionnaires and diaries) and attend all required study visits.
- •At randomization (Visit 2/BV), the subject
- •7.Is confirmed to have at least moderate pain as reflected by a MDP of at least 4.0. The MDP is the mean of 7 consecutive daily assessments of average pain on an 11 point (0-10) NRS with a recall period of 24 hours (item 4 of F GUPI-24h).
- •8.Is confirmed to be willing to comply and has shown to be compliant with study requirements (such as completing questionnaires and diaries, compliance with study drug use and practicing a highly reliable method of birth control) and with attending all study visits.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 260
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 40
排除标准
- •1.A positive pregnancy test (ß-HCG in serum) or be lactating.
- •2.Undergone a CS with hydrodistension or undergone Botox injections in the bladder within 6 months prior to the screening visit.
- •3.Been treated with pentosan polysulphate sodium within 4 weeks prior to the screening visit.
- •4.Had any intravesicular pharmacological treatment for BPS/IC (including but not limited to heparin or dimethyl sulfoxide [DMSO]), or have had other interventions for BPS/IC (including electric stimulation therapy or acupuncture therapy) that may have affected disease symptoms within 3 months prior to the screening visit.
- •5.Cystitis (radiation cystitis, Bacillus Calmette-Guérin (BCG)-induced cystitis, bacterial / tuberculous cystitis, cyclophosphamide cystitis) or had a documented symptomatic bacterial cystitis in the last 3 months prior to the screening visit.
研究者
相似试验
进行中（未招募）
1 期
A study to investigate the effects of lumicitabine (JNJ-64041575) in hospitalized infants and children infected with Respiratory Syncytial Virus (RSV)Respiratory syncytial virus infectionMedDRA version: 20.0Level: PTClassification code 10061603Term: Respiratory syncytial virus infectionSystem Organ Class: 10021881 - Infections and infestationsEUCTR2017-001862-56-DEJanssen-Cilag International NV7
进行中（未招募）
1 期
A Study of the Safety and Efficacy of CNTO 328 and Bortezomib to Bortezomib Alone in Patients With Relapsed or Refractory Multiple Myelomarelapsed or refractory multiple myelomaMedDRA version: 14.0 Level: PT Classification code 10028228 Term: Multiple myeloma System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2006-001904-36-BEJanssen Biologics B.V.290
进行中（未招募）
1 期
This is a clinical trial to evaluate efficacy and safety of a drug activating the immune system MGN1703 in patients with advanced colorectal cancer, which achieved disease stabilization or improvement after initial chemotherapy. The patients will be assigned occasionally (like by tossing a coin) either to treatment with MGN1703 or with placebo, a preparation matching MGN1703, however, without the active substance.Patients with advanced colorectal carcinoma (AJCC Stage IV) with disease control after initial first-line therapyMedDRA version: 14.1Level: LLTClassification code 10010036Term: Colorectal carcinomaSystem Organ Class: 100000004864EUCTR2009-017432-40-ATMOLOGEN AG129
进行中（未招募）
1 期
A study to investigate the effects of lumicitabine (JNJ-64041575) in hospitalized infants and children infected with Respiratory Syncytial Virus (RSV)MedDRA version: 20.0Level: PTClassification code 10061603Term: Respiratory syncytial virus infectionSystem Organ Class: 10021881 - Infections and infestationsRespiratory syncytial virus infectionEUCTR2017-001862-56-FIJanssen-Cilag International NV180
进行中（未招募）
1 期
A clinical study to evaluate safety, tolerability, Pharmacokinetics and Pharmacodynamis of Belcesiran in patients with PiZZ Alpha-1 Antitrypsin Deficiency-Associated Liver DiseasePiZZAlpha-1 Antitrypsin Deficiency Associated Liver DiseaseMedDRA version: 23.1Level: LLTClassification code 10001806Term: Alpha-1 anti-trypsin deficiencySystem Organ Class: 100000004850EUCTR2020-003313-35-ATDicerna Pharmaceuticals, Inc., a wholly owned subsidiary of Novo Nordisk46